Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia Technologies Plc, Company Release, Managers’ Transactions, March 12, 2025 at 05:30 p.m. EET
Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen
Aiforia Technologies Plc has received a notification from Jukka Tapaninen, Aiforia Technologies Plc's Chief Executive Officer, of a transaction made with Aiforia Technologies Plc’s financial instrument, according to the Article 19 of EU Market Abuse Regulation. Detailed information about the transaction is given here under.
____________________________________________
Aiforia Technologies Plc - Managers' transactions - Tapaninen
____________________________________________
Person subject to the notification requirement
Name: Tapaninen, Jukka
Position: Chief Executive Officer
Issuer: Aiforia Technologies Plc
LEI: 743700TJRVBX7420Y723
Notification type: INITIAL NOTIFICATION
Reference number: 743700TJRVBX7420Y723_20250312151858_20
____________________________________________
Transaction date: 2025-03-08
Venue not applicable
Instrument type: SHARE
ISIN: FI4000507934
Instrument name: 2020 II optiot
Nature of the transaction: SUBSCRIPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 28,300 Unit price: 1.3724 EUR
Aggregated transactions
(1): Volume: 28,300 Volume weighted average price: 1.3724 EUR
Further inquiries
Veli-Matti Parkkonen, CFO, Aiforia Technologies Plc,
tel. +358 405 009 878
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com